The detection of changes in tumor glucose metabolism, tumor diameter or tumor volume within a few weeks of commencing treatment has the potential to inform stratification of patient management. For patients with recurrent ovarian cancer, there is an urgent need to identify more effective therapies, and an imaging tool that can robustly identify early response would be of value both in the clinical setting and as a biomarker for drug development. Validation of imaging biomarkers is critical for effective and reliable use in clinical trials. Test/re-test data for measurements of FDG uptake, tumor diameter and tumor volume are essential in order to determine repeatability coefficients, thereby allowing the confident use of these techniques.
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STATEMENT OF TRANSLATIONAL RELEVANCE:
The detection of changes in tumor glucose metabolism, tumor diameter or tumor volume within a few weeks of commencing treatment has the potential to inform stratification of patient management. For patients with recurrent ovarian cancer, there is an urgent need to identify more effective therapies, and an imaging tool that can robustly identify early response would be of value both in the clinical setting and as a biomarker for drug development. Validation of imaging biomarkers is critical for effective and reliable use in clinical trials. Test/re-test data for measurements of FDG uptake, tumor diameter and tumor volume are essential in order to determine repeatability coefficients, thereby allowing the confident use of these techniques.
However, these data have not previously been established for ovarian cancer. This study establishes robust repeatability coefficients for FDG measurements, enabling evidence-based use of PET/CT in stratification of patients into those with a metabolic or volumetric response to treatment.
BACKGROUND
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy and overall survival has not changed significantly over the past 15 years (1) . Most patients present with advanced stage disease and the primary treatment modality is surgical cytoreduction followed by platinum/taxane-based chemotherapy. Relapsed disease is classified by its likely response to further treatment with platinum-based chemotherapy, being either platinum-sensitive or platinum resistant (2) . However, the majority of patients eventually develop progressive platinum-resistance. There is a clear unmet clinical need to identify new treatments for women with ovarian cancer.
Evaluation of the effectiveness of new drug treatments in EOC depends upon assessment of response and progression-free survival. Objective response measurement using RECIST 1.1 criteria (uni-dimensional tumor diameter) is highly validated across many cancer types, as well as having high utility in clinical practice (3;4) . However, it is used inconsistently by regulatory authorities for the purposes of drug registration (5) . There are inherent limitations using unidimensional measurements. Notably, the time taken for tumor shrinkage of 30% is typically in excess of 9 weeks and inevitably delays treatment decisions; particularly in ovarian cancer the shape of the mass may alter during treatment so that the long axis does not reflect change in volume and residual soft tissue along peritoneal or serosal surfaces or in complex masses may be difficult to measure and quantify or may not represent active disease (6) (7) (8) . Despite these recognized limitations, contrast enhanced CT (CECT) is currently the standard of care technique for monitoring response to treatment in ovarian cancer, together with the serum cancer antigen 125 (CA 125) level. Conversely, individual patients with EOC would benefit from the development of more sensitive methods for determining non-responders. Earlier diagnoses of non-response or progressive disease will spare patients from the toxicities associated with futile treatments and access alternative therapies sooner.
FDG-PET/CT has been proposed as an imaging tool for the detection of response, by demonstrating metabolic changes in the tumor, early in the course of treatment (9;10). Early metabolic changes may also have prognostic value. In ovarian cancer, Avril et al found that in the neo-adjuvant setting, by using an a priori stated cut-off value for decrease of standardized uptake value (SUV) from baseline of 20% after the first cycle, median overall survival was 38.3 months in metabolic responders compared with 23.1 months in metabolic non-responders (11).
There was a significant correlation between FDG-PET metabolic response after the first The purpose of this study was to establish the variation in the measurements of FDG uptake and tumor volumes in recurrent ovarian cancer. Our aims were to measure prospectively the test-retest repeatability of quantitative PET measurements (SUVmean, SUVmax) using a standardized volume of interest as well as tumor diameter and tumor volume in a cohort of women with recurrent ovarian cancer treated at 2 sites using different PET/CT instruments.
PATIENTS AND METHODS
The study protocol was reviewed and approved by Cambridgeshire dual center study. All data we collected at the time of origin and collected in a secure database.
The trial was funded and monitored by Merck and Co, which enabled us to conduct the study on the highest level of evidence possible.
Imaging techniques
Following enrolment, a baseline FDG-PET/CT scan was performed, immediately followed by a
contrast-enhanced CT scan (CECT). This was termed baseline 1 (BL1). Patients who did not
have at least one lesion with both, an SUVmax ≥ 2.5 at BL1 FDG-PET scan and a longest diameter lesion of ≥1.5 cm on the BL1 CECT scan were discontinued on the study. In those patients with at least one such lesion, imaging was repeated 1 -7 days later (baseline 2 -BL2)
prior to starting treatment.
FDG-PET imaging
Patients were imaged using a Gemini TF with a 64 channel CT (Philips Healthcare UK) in center between the test and retest PET scans was between 0 to 3 minutes in all but three patients (in whom there was a difference of 6, 7 and 10 minutes respectively), with a mean difference of 1.9 minutes and median of 1 minute. The duration of all emission scans were identical for each PET/CT scanner. The acquisition parameters are given in appendix 2.
Contrast-enhanced CT
The CECT scan was performed directly following the baseline FDG-PET/CT scan including the abdomen and pelvis (and chest if clinically indicated). CECT was defined as a volumetric CT acquisition of the body using a multidetector spiral CT scanner in the portal venous phase following intravenous contrast administration (CECT acquisition parameters are available in supplementary table 2). Images were viewed on 5mm reformatted slices in the axial plane, as per RECIST 1.1 rules, with the option to view in reformatted sagittal or coronal planes. All target lesions were measured in the axial plane (the plane of acquisition). The CECT scans were of sufficient quality to enhance interpretation of FDG-PET scans, permit RECIST assessments, and enable tumor volume image analysis to be performed. For all CECT scans, intravenous iodinated contrast media were used according to local standards of care. If contrast media was contraindicated in a patient, then CECT scan was not performed and the test-retest measurements for RECIST and volumetric analysis could not be evaluated.
Image analysis

Measurement of SUV
FDG uptake in tumor lesions was quantitatively assessed using Standardized Uptake Values 
Image reads
Analysis of the FDG-PET scan and the CECT was performed without knowledge of any specific clinical information apart from the inclusion and exclusion criteria. Two independent reads of the FDG-PET and CECT were made, one being a site read and the other an imaging CRO read, using two different methods. The reads were performed to reflect the practice of trial reporting whereby once targets have been chosen on the first baseline scan, measurements of the same targets are subsequently performed. Target selection was independent between site and CRO as two different reading methods were being evaluated for test retest repeatability.
Site reads
The baseline FDG-PET/CT and CECT were viewed simultaneously by the PET expert and the gynecologic oncology CT expert respectively. A maximum of 5 target lesions were selected from the CECT, maximum two per organ. Although the inclusion criteria required at least one lesion to be SUVmax ≥2.5 and diameter ≥15mm, the criteria used for selecting other target lesions were that each target lesion was FDG avid and of minimal size criteria as defined by RECIST 1.1 (10mm long axis for non-nodal target and 15mm short axis for nodal target).
The longest diameter of each TL was then measured on the CECT according to RECIST rules.
On the FDG-PET images, a spherical VOI with a diameter of 15mm was used to measure the SUVmean and SUVmax of each target, following manual identification of the most avid part of the tumor lesion. All measured parameters were recorded and screen shots of each selected target lesion were stored. The BL1 scan was then closed. The BL2 scan was then opened and each target lesion was measured using to the same technique. Each target lesion was checked with BL1 to ensure that the same target lesions were used, but with blinding to the prior measurements.
Contract Research Organisation reads
CRO reads for SUV measurements and TD were considered the secondary reads. CECT volumes and FDG-PET images were read by a single independent radiologist with significant experience in reading CT-volumes and FDG-PET. CECT images were assessed for target lesion diameter and volume. The CT lesion selection criteria followed the guidelines set forth by the RECIST allowing selection of up to 10 lesions ≥10mm to be selected with a maximum of 5 per organ. The FDG-PET images for this study were used to assess the SUVmax and SUVmwa for up to 10 lesions. As long as appropriate, the same target lesions were chosen on PET and CECT. However, when an FDG-avid lesion was not suitable for RECIST measurements or vice versa, measurements on the other modality were not enforced. Thirty-five percent of subjects had different numbers of targets in the two modalities (28% had additional FDG-PET targets, 7% had additional CECT targets). All but one PET avid target had an SUVmax ≥2.5. CECT images were used to delineate the target lesions which were described as series of Regions of Interest (ROIs), drawn on each slice where present, to ensure the entire volume of the lesion was assessed (VOI). ROIs were created using a semiautomatic approach combining freehand and autosegmentation, which allowed adjustment by a radiologist. The ROIs for target lesions provided longest diameter for non-nodal lesions, longest short axis diameter for nodal lesion and volume assessment of the individual target lesions. The lesion locations from CECT images were used to follow consistently the target lesions on sequential imaging. FDG-PET images were viewed along with the CECT images to confirm the selection of the same lesion selected on CECT, up to the extent possible to meet lesion selection criteria. Metabolic volumes were determined by an isocontour of 25% of the SUVmax.
Statistical methods
Repeatability
When the number of target lesions increases, the sum of target lesions (in terms of SUV and tumor size) also increases. As a result, correlation between repeated scans may be inflated due to different numbers of target lesions across patients. Therefore, for repeatability assessment, the average was used to summarize measures across multiple target lesions within a scan.
The repeatability of SUV and tumor size measurements was assessed based on the two baseline scans. The Kendall tau and Shapiro-Wilk tests were performed on both original and log-transformed data and the log-transformed data were closer to normality and constant variance. Scatter plots (Scan 1 vs Scan 2) with a 45° line through the origin and Bland-Altman plots (difference vs mean) were generated. Concordance correlation coefficient (CCC), within subject standard deviation (SD), and within-subject coefficient of variation (CV) were derived.
The difference between two baseline measurements for the same patient was considered to be within the normal variation for 95% of pairs of observations. The repeatability coefficient was estimated to be twice the standard deviation of the paired differences. On a logarithmic scale, expressed as a percent change from baseline, the repeatability coefficient was [1 -exp (-2 * SD diff )] x 100%.
RESULTS
21 patients underwent two baseline imaging studies. In one case, the diagnostic CECT component could not be done with intravenous contrast media on BL2, and therefore the CT components (TD and TV) were not evaluated for repeatability, with a final number of 20 patients evaluable for TD and TV. The number of target lesions in each data set is provided in table 1.
For the primary site reads, the mean diameter of target lesions was 32mm and all target lesions were > 15mm except for 4 which were between 11.1 and 14.6mm. 
DISCUSSION
FDG-PET is increasingly being used as a biomarker for treatment monitoring in cancer patients (13) (14) (15) . In order to identify a metabolic response it is necessary to establish the normal variation of tumor FDG uptake prior to therapeutic intervention. We found a high test-retest repeatability of quantitative measures of tumor glucose metabolism (FDG uptake) using different parameters derived from Standardized Uptake Values (SUV) in ovarian cancer. This is in line with previous reports who observed a good repeatability of FDG uptake measurements in other tumors, as reported in a recent meta-analysis (12) . The first study addressing this issue dates back in 1999 and included 16 patients with different tumor types who underwent FDG-PET within 10 days without anti-cancer treatment in-between (16) . In that study, the differences of repeated measurements were approximately normally distributed for all SUV parameters with a SD of the mean percentage difference of about 10%. The authors concluded that changes of a SUV parameter outside the 95% normal range may be used to define a metabolic response to therapy.
The PET technology has advanced since then from stand-alone PET scanners to combined PET-CT and subsequent studies have shown a high repeatability for measuring tumor FDG uptake using FDG-PET/CT in a limited number of patients (17;18) . This is the first study to address this issue in ovarian cancer. The abdomen is particularly difficult to quantitatively evaluate for tumor FDG uptake due to physiologic excretion of FDG via the urinary tract and due to variable physiologic FDG uptake within bowel structures. Ovarian cancer often presents with serosal implants, which can be subject to motion, potentially compromising longitudinal FDG- shape can be challenging to evaluate for changes in size using uni-dimensional line lengths.
An important strength of our study is that we fully utilized the capability of FDG-PET/CT by performing a CECT after completion of the PET data acquisition. No such CECT repeatability study has previously been performed in ovarian cancer patients. Changes in tumor size are generally believed to occur at later time points after start of treatment as compared to metabolic changes. Tumor size measurements can be affected by partial volume artefacts particularly when the target lesion is small when using a CT slice thickness of 5mm and in addition, some bowel movement can occur during the time of CT acquisition further compounding partial volume artefacts. However, we found a test retest variation as low as 8.8% for tumor diameter when measured sequentially. We also assessed changes in tumor volume and found a test retest variation of 28.1%; despite this wider variation between repeat measurements in volume, changes in tumor volume following treatment may be more sensitive than changes in diameter and establishing the repeatability coefficient is thus highly relevant. It is important to point out that defining a tumor volume in the abdomen is particularly difficult and automated software algorithms for that purpose are currently under investigation. Such algorithms which render volumetric and tissue density measurements have been successfully used in the lungs: a study demonstrated that a semi-automated algorithm was able to accurately segment 14 out of 15 patient tumors imaged in thin section CT scans (7;25) . Follow-up CT at 3 weeks after start of gefitinib showed that 73% of patients had an absolute change in tumor volume of at least 20%;
in contrast, only 7% and 27% of patients showed similar changes in their tumor sizes using either uni-dimensional or bi-dimensional measurements, respectively.
An important strength, but also a potential weakness of our study is the highly standardized imaging environment with strong academic support. Highly experienced PET and CT reader have jointly interpreted the images, which might at least have partially contributed to the superiority of tumor size measurements over semi-automated volume measurements.
Nevertheless, our data also demonstrate that a company based image analysis (CRO read)
produced results comparable to the site reads. Our approach in this regard is novel as it directly allowed a comparison between an academic and a commercial setting for image analysis.
The FDG uptake measurements are affected by numerous factors and a meticulous quality assurance program needs to be place in order to achieve repeatable PET measurements. This includes patient preparation, obtaining blood glucose levels, measuring precisely the amount of injected FDG activity as well as scanner calibration amongst others. Of note, a recent study found much greater variance of SUV uptake measurements in a clinical PET setting when compared to ideal study settings (26) . The variation in FDG uptake time is an important limitation in the repeatability of FDG-PET and specific efforts need to be place to ensure timely procedures. It is of crucial importance for oncologists to work closely together with their imaging group to ensure that procedures are in place to enable PET treatment monitoring studies.
A limitation of our study is that we did not independently repeat each of the two reading methods by a further reader, but rather we compared two independent reading methods.
However, we have attempted to recreate the method used in standard trial sequential reporting to closely reflect clinical practice. Also, the selection of target lesions on the CECT was aided by simultaneous viewing of the PET images which could have resulted in an increase in the detection of lesions on CT.
CONCLUSION:
We have shown excellent test/retest repeatability for FDG-PET/CT quantitative measurements in recurrent ovarian cancer across two independent reading methods. The repeatability coefficients suggest that a decrease in FDG uptake (SUV) of 15-20% from baseline and decrease in tumor size between 10-15% could be used to determine early tumor response. 
